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Abstract
Objective—To detect the etiologic agents of acute gastroenteritis (AGE) in children using broad 
molecular-based techniques, and compare clinical presentations among etiologies.
Study design—This was a prospective population-based surveillance study of children aged <6 
years with AGE conducted between 2008 and 2011 as part of the New Vaccine Surveillance 
Network. Stools from patients and healthy controls were tested for 21 gastrointestinal pathogens 
using the analyte-specific reagent Gastrointestinal Pathogen Panel and an additional reverse 
transcription real-time polymerase chain reaction assay for sapovirus and astrovirus.
Results—Of the 216 stool samples from patients with AGE, 152 (70.4%) tested positive for a 
pathogen, with norovirus genogroup II (n = 78; 36.1%) and Clostridium difficile (n = 35; 16.2%) 
the most common pathogens detected. Forty-nine patients (22.7%) tested positive for more than 1 
pathogen, including 25 (71%) with a C difficile detection. There were no significant clinical 
differences among the patients with no pathogen detected, those with a single pathogen detected, 
and those with ≥2 pathogens detected.
Conclusion—Using a broad molecular testing approach, high rates of enteropathogens were 
detected in children with AGE, dominated by norovirus genogroup II and C difficile. Coinfections 
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were common but had no identifiable impact on clinical manifestations. As routine diagnostics of 
AGE progressively evolve toward nucleic acid–based pathogen detection, ongoing systematic 
studies are needed to better analyze the clinical significance of results.
Acute gastroenteritis (AGE) is one of the most common infectious diseases of humans, with 
approximately 5 billion episodes of diarrhea occurring worldwide annually, accounting for 
15%-30% of all deaths in some countries.1 Viral AGE accounts for approximately 3%-5% of 
all hospital days and 7%-10% of hospitalizations of children each year in the US.1,2 
Norovirus (a member of the family Caliciviridae) has become the leading cause of 
gastroenteritis among young US children since the implementation of universal rotavirus 
immunization of infants beginning in 2006.3 In addition, the rates of Clostridium difficile 
infection (CDI) in children are on the rise. A recent national database study of hospitalized 
children found an increase in incidence from 24 to 58 per 10 000 discharges per year 
between 2003 and 2012.4
In a large proportion of patients, the etiologic agent of AGE is unidentified. In 2009-2010, a 
total of 2259 AGE outbreaks were reported to the Centers for Disease Control and 
Prevention (CDC).5 No etiologic agent was identified in samples from approximately 40% 
of these outbreaks, underscoring the need to broaden testing for additional enteric 
pathogens. Recent work has demonstrated that polymerase chain reaction (PCR)-based 
testing has better sensitivity than conventional methods of enteropathogen detection6-8; 
however, the time and materials required to test for each of the common causes of AGE 
individually makes this approach impractical for routine clinical application. In addition, 
concerns remain that for certain pathogens (Clostridium difficile in particular), the superior 
sensitivity of nucleic acid–based testing creates the potential for overdiagnosis and 
overtreatment.9 Finally, the identification of some pathogens in asymptomatic control 
children makes the interpretation of their detection in symptomatic patients more 
problematic.
Several multiplex nucleic acid–based strategies to test for multiple gastrointestinal pathogens 
have been devised to surmount the diagnostic challenges inherent to the causal diversity of 
AGE.10-14 The recently developed Gastrointestinal Pathogen Panel (GPP; Luminex 
Molecular Diagnostics, Toronto, Ontario, Canada) allows the simultaneous detection of 19 
unique gastrointestinal pathogen sequence targets in fecal specimens using multiplex PCR 
amplification.15
In this study, we used the GPP and an additional multiplex reverse-transcription real-time 
PCR (RT-rtPCR) analysis for the detection of sapovirus and astrovirus to identify 
enteropathogens in fecal specimens from children aged 2 weeks to 6 years who were 
prospectively enrolled in a multiyear surveillance project for AGE at the study site in 
Nashville, Tennessee. In addition, we tested samples from healthy asymptomatic children 
and a subgroup of patients with known rotavirus gastroenteritis to determine the degree of 
positive testing in these 2 unique control cohorts.
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Methods
The study population comprised children living in Davidson County, Tennessee who 
received care at Monroe Carell Jr Children's Hospital at Vanderbilt (MCJCHV) between 
May 1, 2008, and June 30, 2011, excluding October 2009. The age at study enrollment 
ranged between 14 days and <5 years through October 31, 2010, and between 14 days and 
<6 years from November 1, 2010, through completion of the study. Prospective, active 
surveillance of children occurred as part of the New Vaccine Surveillance Network 
(NVSN).16 Institutional Review Board approval for the study was obtained from Vanderbilt 
University and the Centers for Disease Control and Prevention.
Children with ≥3 loose stools and/or ≥1 episode of vomiting within a 24-hour period and 
presenting within 10 days of illness onset were eligible for enrollment. Children seen in the 
inpatient, emergency department, and outpatient settings were included. Children who likely 
had noninfectious diarrhea, had a known clinical immunodeficiency, had been previously 
enrolled for the same gastroenteritis episode, or had been transferred from another institution 
after >48 hours of hospitalization were excluded from the study. Stool specimens, provided 
almost exclusively in the form of soiled diapers, were collected at the time of enrollment or 
as soon as possible within 14 days of AGE symptom onset.
Healthy controls were children aged <5 years17 enrolled between May 1, 2009, and August 
31, 2009, at the time of a well-child visit at MCJCHV. These children had no known clinical 
immunodeficiency, no symptoms of an acute respiratory infection (ie, cough, congestion, 
sore throat, wheezing, or rhinorrhea) within 3 days of enrollment, and no symptoms of AGE 
within 14 days of enrollment.
Specimens from an additional subset of children with AGE enrolled in the NVSN between 
2006 and 2009 and who tested positive for rotavirus by enzyme immunoassay (EIA) 
(Rotaclone; Meridian Bioscience, Cincinnati, Ohio) were also evaluated for additional 
pathogens using the methods described above.
Demographic, epidemiologic, and clinical data were collected for all subjects, as were 
provider-verified rotavirus vaccination records.
Specimen Processing
Specimens were refrigerated or frozen within 8 hours of collection and stored at −20°C for 
approximately 2 weeks until processing. Stool suspensions (10%) were prepared in 
Rotaclone EIA diluent or phosphate-buffered saline and tested immediately for the presence 
of rotavirus in accordance with manufacturer's instructions. Scant or liquid specimens 
insufficient for testing were recovered using a plastic syringe barrel and plunger to forcefully 
pass 10 mL of Earl's balanced salt solution through an excised piece of soiled liner, resulting 
in a fecal eluate. Residual clarified stool suspensions were stored at −80°C.
Nucleic Acid Extraction
Total nucleic acid was extracted from 10% clarified stool suspensions by preliminary 
mechanical disruption using Presells Soil Mix Beads (Cayman Chemical, Ann Arbor, 
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Michigan), followed by purification using the Magma Total Nucleic Acid Isolation Kit 
(Applied Biosystems, Carlsbad, California) and Magma Express 96 (Applied Biosystems) 
automated extraction system in accordance with the manufacturer's instructions. Before 
extraction, each specimen was seeded with 10 μL of MS2 bacteriophage lysate 
(ZeptoMetrix, Franklin, Massachusetts) at 1 × 109 PFU/mL as a processing and 
amplification control to confirm the success of nucleic acid extraction and the absence of 
endogenous PCR inhibitors.
Enteropathogen Detection
The gastrointestinal pathogens included in our analysis are summarized in Table I. In 
addition, we also tested for astrovirus and sapovirus using a multiplex reverse-transcription 
quantitative polymerase chain reaction assay on an Applied Biosystems 7500 Real-Time 
PCR platform. MS2 was concurrently amplified in a separate reaction according to 
published methods.17 GPP testing was performed as described previously with some 
modifications to the PCR master mix and analysis conditions.15 In brief, each PCR reaction 
contained 0.167 μL of each ASR (Luminex Corporation, Austin, Texas), 7.5 μL of 5× RT-
PCR buffer (Qiagen, Valencia, California), 1.45 μL of 10 mM deoxyribonucleotide 
triphosphate mixture (Qiagen), 0.5 μL of bovine serum albumin (New England Biolabs, 
Ipswich, Massachusetts), 0.1 μL of 5M tetramethylammonium chloride (Sigma-Aldrich, St 
Louis, Missouri), 2 μL of OneStep RT-PCR enzyme (Qiagen), and 0.11 μL of DNAse/
RNAse free water. The total reaction volume was 25 μL (15 μL of master mix plus 10 μL of 
extracted nucleic acids). Target-specific PCR products were detected using Luminex xMAP 
technology with fluorescent microspheres and the Luminex 100/200 microfluidics system, 
with gating set at 7000-20 000 according to the Luminex protocol. Data were analyzed using 
xPONENT 3.1 and TDAS LSM software packages (Luminex Corporation, Austin, Texas). 
MS2 sequences were coamplified in the same reaction tube with xTAG targets. 
Determination of a positive specimen is detailed in Table II (available at www.jpeds.com).
Statistical Analyses
The Pearson χ2 test for categorical variables and Kruskal-Wallis test for continuous 
variables were used for comparisons of demographic, epidemiologic, and clinical 
characteristics, with a 2-sided P value < .05 considered to indicate statistical significance. In 
the event of a statistically significant finding using the Kruskal-Wallis test, additional 
pairwise comparisons were performed using the Wilcoxon rank-sum test with Bonferroni 
correction to adjust for multiple comparisons.
Results
The group of 216 children with AGE included 99 females (46%) and 117 males (54%) and 
had a median age of 16 months (IQR, 6-27 months). Seventeen patients (8%) had a history 
of prematurity; 150 patients (69%) had a history of breast-feeding, and 23 (11%) were being 
breast-fed at the time of study enrollment. One or more enteropathogens were detected in 
stools from 152 of the 216 children with AGE (70.4%) enrolled during study years 
2008-2011, vs 4 of the 36 asymptomatic control patients (11%) enrolled in 2009. A viral 
pathogen was present in 138 children in the AGE group (63.9%) compared with only 1 child 
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in the control group (3%), whereas a bacterial pathogen of AGE was detected in 47 cases 
(21.8%) vs 3 controls (8%). Episodes of detection in asymptomatic children included 1 
norovirus GII and 3 C difficile. Among the 21 asymptomatic infants aged <12 months, 3 
(14%) tested positive for C difficile.
Of the 138 samples from patients with AGE cases who tested positive for a virus, norovirus 
GII was detected in 78 cases (57%) and rotavirus was detected in 28 cases (20%) (Figure 1). 
C difficile was identified in 35 (75%) of all samples that tested positive for enteric bacteria. 
All specimens tested negative for protozoan parasites. Forty-nine patients with AGE (22.7% 
of the total cohort) tested positive for more than 1 pathogen. Of these, 7 patients had 3 
pathogens detected. Of the 35 patients who tested positive for C difficile, 25 (71%) also 
tested positive for at least 1 other pathogen. The most common combination of pathogens 
was norovirus GII and C difficile (Figure 2). C difficile was more prevalent in children aged 
<3 years, with 94% of C difficile detections in these young children. More patients were 
enrolled during the fall and winter months, more than one-half of whom had a viral etiology 
(Figure 3; available at www.jpeds.com). In contrast to the nominal rotavirus positivity 
among AGE patients enrolled during the 2009-2010 winter and spring seasons, in which 
rotavirus was detected in only 2% of patients, 31% of AGE cases enrolled during the 
2010-2011 winter and spring seasons were rotavirus-positive. This marked fluctuation in 
rotavirus prevalence corresponds with a roughly biennial epidemic pattern of rotavirus in the 
US that has emerged in the postvaccine era.18
In patients with AGE, comparisons of those with a single viral pathogen, a single bacterial 
pathogen, coinfection with more than 1 pathogen, and no pathogen detected based on 
demographic and clinical characteristics (Table III), no statistically significant differences in 
race or sex were identified. However, there were statistically significant differences in age (P 
= .04), number of hospital days in those patients who required admission (P = .002), and 
maximum number of diarrhea episodes in 24 hours (P = .015), but these findings did not 
persist after pairwise comparisons were completed and a Bonferroni correction was applied. 
Patients with a single viral pathogen identified were more likely to experience vomiting 
(91%), whereas those with a single bacterial pathogen identified were more likely to have 
fever (85%), but these findings were not statistically significant. Asymptomatic control 
patients were also compared on demographic characteristics, and there were no statistically 
significant differences in terms of age, race, or gender when comparing patients with a 
bacterial detection, viral detection, or no pathogen identified.
Stools from 64 children with EIA-confirmed rotavirus AGE in 2006-2009 were included in 
the analysis as a reference for the frequency and spectrum of copathogens in the presence of 
a clear cause for AGE. Additional enteropathogens identified in this rotavirus-positive 
population included C difficile in 11 patients (17%) and Campylobacter in 1 patient (2%). In 
this cohort, the C difficile–positive children were younger than the C difficile–negative 
children, but the difference was not statistically significant (14.8 months vs 18.0 months; P 
= .39, Wilcoxon rank-sum test).
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Discussion
Despite the substantial health burden of pediatric AGE, the etiologic profile of AGE in 
children remains poorly defined. Newer technologies, such as multiplex molecular assays, 
allow for rapid and sensitive analysis of AGE pathogens and are now commercially available 
and Food and Drug Administration–cleared. Previous studies have validated the analytical 
sensitivity and specificity of these methods, but few have addressed the clinical significance 
of the results.10-13
Using multitarget molecular assays, our study identified enteropathogens in 70.4% of our 
cohort of children aged 14 days through 6 years with symptomatic AGE. This is in stark 
contrast to a previous study using primarily nonmolecular methods such as culture, 
microscopy, and cytotoxicity assays to identify pathogens in symptomatic children with 
AGE.19 Using these traditional approaches, a pathogen was detected in only 29 of 254 ill 
children (11.4%), illustrating the superior sensitivity of molecular as-says. In the present 
study, norovirus GII was the most common infection identified, with 36.1% of stools testing 
positive. Since implementation of routine rotavirus vaccination in the United States, 
norovirus GII has emerged as the predominant cause of AGE among young children.17 
Norovirus was detected in 21% of 1295 children seeking medical attention for AGE in 
2009-2010 (including 20 of 57 [35%] outpatients evaluated at MCJCHV), whereas rotavirus 
was identified in only 12% of these patients.3 The high rate of norovirus in this population 
supports the need for an effective norovirus vaccine, as well as appropriate norovirus 
infection control measures.
Pediatric CDI is on the rise in both inpatient and outpatient settings.20-23 C difficile was the 
most common bacterial infection identified in our cohort, present in 16.2% of stools of 
children with AGE. Although C difficile is a well-established cause of AGE in children, it is 
also detected in 25%-80% of infants aged <1 year without AGE symptoms, with lower 
colonization rates in toddlers.24-26 High rates of colonization in children with comorbidities 
and/or frequent hospitalizations also have been reported, with rates as high as 30%-55% in 
pediatric oncology patients, 17% in children with inflammatory bowel disease, and 24% in 
hospitalized children.27-29 In the present study, we found C difficile colonization in 8% of 
healthy asymptomatic children aged 0-51 months and in 14% of children aged <12 months.
In addition, C difficile coinfections were common in our study population. Twenty-five of 
the 35 patients with C difficile detection (71%) were also positive for an additional 
enteropathogen. Conversely, C difficile was detected in 17% of children with an EIA-
confirmed rotavirus infection. These findings are in agreement with a recent study of US 
children with AGE, in which nearly 25% of those positive for C difficile had a virus detected 
concomitantly.30 Also in that study, the children with a coinfection were younger and had a 
higher bacterial burden of C difficile than those with C difficile alone, yet they were 
otherwise clinically indistinguishable. Similarly, in our study, children with multiple 
pathogens detected were no more likely than other children with AGE to have fever, be 
hospitalized, or experience vomiting. In addition, we found no significant differences in 
clinical characteristics between children with C difficile detection alone and those with C 
difficile detected with another enteropathogen, although our analysis was limited by a small 
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sample size (Table IV; available at www.jpeds.com). Unfortunately, antibiotic use and 
hospitalization history, which are relevant to CDI, were not collected in the initial NVSN 
study and thus were unknown in these patients. Interestingly, we observed high rates of 
vomiting in our cohort of children with C difficile detection alone (10 of 11; 91%), higher 
than previously reported rates.19,31 Reasons for this pattern are unclear, but the results may 
suggest a non–C difficile etiology of AGE in these patients or a higher rate of vomiting in 
younger children with CDI.
A recent switch from toxin-based C difficile testing to molecular tests has also raised 
concerns, as hospitals have reported a 50%-100% increase in CDI rates with this 
transition.32,33 A recent study in adults found that virtually all CDI-related complications 
occurred in patients with a positive toxin immunoassay.9 In that study, patients with a 
positive molecular test result and a negative toxin immunoassay were clinically comparable 
with those without CDI. The authors concluded that the exclusive reliance on molecular tests 
for CDI diagnosis resulted in overdiagnosis, overtreatment, and associated increased 
healthcare costs. In the present study, we found high C difficile detection rates in young 
children and those with other infectious detections. This information, coupled with a lack of 
clinical differences, suggests that at least a proportion of our C difficile detections in 
children with AGE reflect mere colonization. With the ever-expanding commercialization of 
multiplex nucleic acid–based testing for gastrointestinal infections, ongoing refinements to 
the clinical interpretation will be required, particularly in the setting of CDI.
Of note, for the majority of patients with AGE, an etiologic diagnosis will not affect 
management. Indeed, rotavirus laboratory confirmation and coding are uncommon in 
clinical settings.34 In children, etiologic testing is often reserved for those who are more 
severely ill or have additional comorbidities. In these situations, testing for a constellation of 
possible causes may help expedite definitive management compared with traditional 
laboratory methods or single-target molecular assays.
Our study has several limitations. Although we comprehensively assessed the most common 
causes of AGE in our cohort of children from Davidson County, Tennessee, there is likely to 
be regional variation in the spectrum of pathogens, and thus our study may lack external 
validity. The duration of enrollment of healthy controls was also limited and might not 
reflect seasonal trends. In addition, although our cohort of healthy controls did not exhibit 
any signs or symptoms of AGE within 14 days before enrollment, it is possible that the few 
instances of pathogen detection were related to persistent shedding from a preceding AGE 
episode. The small number of control patients in our study, along with the lack of clinical 
information preceding the 14-day symptom-free window, limit our ability to draw additional 
conclusions about subclinical pathogen shedding and relevance of positive test results in 
asymptomatic patients. This same principle applies to the AGE population, in which the 
high sensitivity of nucleic acid amplification testing might detect genetic material from 
pathogens that are nonviable or associated with a previous, clinically resolved infection. Of 
note, no etiologic agent was identified in 30% of our patients with AGE. These children may 
have been ill owing to noninfectious vomiting and/or diarrhea, or the AGE symptoms may 
have been caused by novel enteric pathogens not included in our analysis.
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Finally, we used the Kruskal-Wallis test for statistical analyses of continuous variables 
among infection groups. If there was a statistically significant finding, then additional 
pairwise comparisons were performed using the Wilcoxon rank-sum test with Bonferroni 
correction. This is a notably conservative statistical method, which may carry an increased 
risk of a type II error and failure to reject a false null hypothesis.
Despite the substantial burden of AGE in children, the full spectrum of causative pathogens 
and their clinical implications have not been fully defined. Using GPP and a duplex RT-
rtPCR assay for sapovirus and astrovirus, we identified an enteropathogen in 70% of 
children with AGE, compared with only 11% of asymptomatic controls. Detection of enter-
opathogens in a substantially larger proportion of patients with AGE compared with 
asymptomatic controls supports the general clinical validity of multitarget molecular assays 
for the etiologic diagnosis of pediatric AGE; however, these results also demonstrate that the 
presence of microbial nucleic acid is not a perfect diagnostic biomarker, because healthy 
children may also test positive for known pathogens. Although PCR-based analysis of stool 
specimens using a multiplex approach offers extended insights into current potential causes 
of diarrheal illness in young children. Challenges in data interpretation remain, particularly 
those involving coinfections and C difficile.
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Figure 1. 
Distribution of detected pathogens in the patients with AGE (n = 216).
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Figure 2. 
Frequency of coinfections in the patients with AGE.
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Figure 3. 
Seasonal variation of pathogen detection in the patients with AGE (n = 210). Owing to the 
low numbers of specimens tested, specimens from spring 2008, spring 2009, and summer 
2009 are not shown for clarity.
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Table I
Gastrointestinal pathogen targets
Bacteria Viruses Parasites
Campylobacter spp Adenovirus serotypes 40 and 41 Cryptosporidium spp
C difficile (toxins A and B) Astrovirus* Entamoeba histolytica
Enterotoxigenic E coli (heat-labile and heat-stable toxins) Norovirus GI Giardia spp
E coli O157 Norovirus GII
Salmonella spp Rotavirus group A
Shiga toxin–producing E coli (Shiga toxins 1 and 2) Sapovirus*
Shigella spp
Vibrio cholera
Yersinia enterocolitica
GI, Genogroup I.
*
Targets were detected using the Analyte-Specific Reagent GI Panel with the exception of astrovirus and sapovirus, for which a duplex RT-rtPCR 
assay was used.13
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Table II
Determination of positive specimens
Assay Pathogen Determination of specimen positivity
GPP* performed at 
Vanderbilt with or without 
GPP and/or single-plex PCR 
performed at the Luminex 
Molecular Diagnostics 
Laboratory
Campylobacter spp Screen-positive at Vanderbilt using GPP and subsequently 
confirmed at the Luminex Molecular Diagnostics 
Laboratory using single-plex and/or multiplex PCR with 
primers specific for pathogenic Campylobacter species 
(jejuni, coli, and lari)*
C difficile Codetection of toxin A and toxin B or reproducible 
detection of either toxin A or toxin B
Enterotoxigenic E coli (heat-labile and heat-
stable toxins)
Median fluorescence intensity ≥2 times the target-specific 
positivity threshold
E coli O157
Salmonella spp
Shiga toxin-producing E coli (Shiga toxins 1 
and 2)
Vibrio cholerae
Shigella spp
Yersinia enterocolitica
Adenovirus serotypes 40 and 41
Norovirus GI
Norovirus GII
Rotavirus group A
Cryptosporidium spp
Entamoeba histolytica
Giardia lamblia
Duplex RT-rtPCR assay 
performed at Vanderbilt
Astrovirus Target-specific Ct value ≤35
Sapovirus
GI, Genogroup I.
*
It was discovered that Campylobacter primer sets in the GPP cross-reacted with nonpathogenic Campylobacter species. Therefore, 
Campylobacter-positive specimens were sent to the Luminex laboratory for confirmatory PCR testing using targets specific for pathogenic species. 
The final analysis of Campylobacter infections reflects only those specimens containing pathogenic species. One positive specimen was unavailable 
for confirmatory PCR and treated as negative.
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Table III
Demographic and clinical characteristics of patients with AGE by pathogen
Characteristics Viral pathogen 
detected (n = 90)
Bacterial 
pathogen detected 
(n = 13)
Coinfection 
detected (n = 49)
No pathogen 
detected (n = 64)
P value
Age, mo, median (IQR) 19.5 (9-30) 10 (4-16) 12 (8-22) 14.5 (3-26)
.04*
Male sex, n (%) 51 (57) 6 (46) 24 (49) 36 (56)
.75†
Race, n (%)
.09†
    White 32 (36) 3 (23) 15 (31) 16 (25)
    Black 26 (29) 6 (46) 26 (53) 27 (42)
    Other 32 (36) 4 (31) 8 (16) 21 (33)
Breastfeeding, n (%)
    Current 9 (10) 1 (8) 1 (2) 12 (19)
.14†
    Ever 58 (64) 8 (62) 35 (71) 49 (77)
.38†
Daycare attendance, n (%) 27 (30) 3 (23) 20 (41) 16 (25)
.29†
Hospitalization, n (%) 26 (29) 6 (46) 14 (29) 24 (38)
.44†
Length of hospitalization, d, median 
(IQR)
1 (1-2); n = 26 0.5 (0-1); n = 6 1 (1-2); n = 14 2 (1-3); n = 24
.002*
Fever during illness, n (%) 50 (56) 11 (85) 29 (59) 43 (67)
.38†
Highest temperature, °F, median 
(IQR)
102 (101-103); n = 
39
101 (100-102); n = 
7
102 (101-103); n = 
25
102 (101-103); n = 
39 .26
*
Vomiting during illness, n (%) 82 (91) 11 (85) 41 (84) 53 (83)
.43†
Maximum number of episodes of 
vomiting in 24 h, median (IQR)
5 (3-8); n = 80 3.5 (2-6); n = 8 4 (3-6.5); n = 40 4 (2-6); n = 51
.54*
Maximum number of diarrheal 
episodes in 24 h, median (IQR)
6 (4-8); n = 74 6.5 (4-15); n = 10 6.5 (3.5-10); n = 40 3.5 (2-7); n = 46
.015*
Rotavirus vaccine status, n (%)
.08†
    Yes 64 (71) 9 (69) 40 (82) 36 (56)
    No 20 (22) 4 (31) 8 (16) 25 (39)
    Unknown 6 (7) 0 (0) 1 (2) 3 (5)
*
Kruskal-Wallis test.
†
Pearson test.
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Table IV
C difficile detections
Variables C difficile detection alone (n = 11) C difficile coinfection (n = 24) P value
Hospitalization, n (%) 5 (45) 7 (29)
.35*
Length of hospitalization, d, median (IQR) 1 (1-2); n = 7 1 (0-1); n = 5
.37†
Fever during illness, n (%) 8 (73) 13 (54)
.30*
Highest temperature, °F, median (IQR) 101.5 (101-102); n = 6 102 (100-102); n = 10
.69†
Vomiting during illness, n (%) 10 (91) 21 (88)
.77*
Maximum number of episodes of vomiting in 24 hours, 
median (IQR)
3 (2-5.5); n = 8 4 (3-7); n = 20
.24†
Maximum number of diarrheal episodes in 24 hours, 
median (IQR)
6 (2-15); n = 7 5 (3-8.5); n = 20
.76†
*
Pearson test.
†
t test.
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